-
EP4313126
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4313126
| EP4313126 - COMBINATION OF A CAR T CELL THERAPY AND AN IMMUNOMODULATORY COMPOUND FOR TREATMENT OF LYMPHOMA [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 05.01.2024 Database last updated on 19.10.2024 | |
| Former | The international publication has been made Status updated on 10.10.2022 | ||
| Former | unknown Status updated on 23.05.2022 | Most recent event Tooltip | 31.05.2024 | Change: Validation states | published on 03.07.2024 [2024/27] | 31.05.2024 | Change - extension states | published on 03.07.2024 [2024/27] | Applicant(s) | For all designated states Juno Therapeutics, Inc. 400 Dexter Ave. N, Suite 1200 Seattle, WA 98109 / US | [2024/06] | Inventor(s) | 01 /
TREDE, Nikolaus Sebastian Seattle, Washington 98109 / US | 02 /
PULHAM, Tim 2017 Boudry / CH | 03 /
WU, Fan Summit, New Jersey 07901 / US | 04 /
POURDEHNAD, Michael San Francisco, California 94158 / US | 05 /
DESTEFANO, Joseph Andrew Summit, New Jersey 07901 / US | 06 /
CARRANCIO ANTON, Maria Soraya San Diego, California 92121 / US | 07 /
BUCHHOLZ, Tonia Jane San Francisco, California 94158 / US | 08 /
PORTS, Michael Seattle, Washington 98109 / US | 09 /
QIN, Jim Seattle, Washington 98109 / US | 10 /
DUBOWY, Ronald Seattle, Washington 98109 / US | 11 /
BRAND, Nicolas 2017 Boudry / CH | [2024/06] | Representative(s) | Mewburn Ellis LLP Aurora Building Counterslip Bristol BS1 6BX / GB | [N/P] |
| Former [2024/06] | Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB | Application number, filing date | 22723232.9 | 29.03.2022 | [2024/06] | WO2022US22358 | Priority number, date | US202163167599P | 29.03.2021 Original published format: US 202163167599 P | US202163277134P | 08.11.2021 Original published format: US 202163277134 P | [2024/06] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2022212384 | Date: | 06.10.2022 | Language: | EN | [2022/40] | Type: | A1 Application with search report | No.: | EP4313126 | Date: | 07.02.2024 | Language: | EN | The application published by WIPO in one of the EPO official languages on 06.10.2022 takes the place of the publication of the European patent application. | [2024/06] | Search report(s) | International search report - published on: | EP | 06.10.2022 | Classification | IPC: | A61K39/00, A61K35/17, A61K31/5377, A61P35/00 | [2024/06] | CPC: |
A61K31/5377 (EP,IL,KR,US);
A61K39/464412 (EP,IL,KR,US);
A61K39/4611 (EP,IL,US);
A61K31/675 (EP,IL,US);
A61K31/7076 (EP,IL,US);
A61K39/4631 (EP,IL,KR,US);
A61P35/00 (KR,US);
A61P35/02 (KR);
C07K14/7051 (US);
C07K14/70521 (US);
C07K14/70578 (US);
C07K16/2803 (US);
A61K2039/804 (EP,IL);
A61K2239/26 (US);
A61K2239/38 (KR,US);
A61K2239/39 (US);
A61K2239/48 (EP,IL,KR);
A61K2300/00 (EP,IL,KR);
| C-Set: |
A61K31/5377, A61K2300/00 (EP);
A61K31/675, A61K2300/00 (EP);
A61K31/7076, A61K2300/00 (EP)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2024/06] | Title | German: | KOMBINATION AUS EINER CAR-T-ZELLTHERAPIE UND EINER IMMUNMODULATORISCHEN VERBINDUNG ZUR BEHANDLUNG VON LYMPHOMEN | [2024/06] | English: | COMBINATION OF A CAR T CELL THERAPY AND AN IMMUNOMODULATORY COMPOUND FOR TREATMENT OF LYMPHOMA | [2024/06] | French: | COMBINAISON D'UNE THÉRAPIE PAR LYMPHOCYTES CAR-T ET D'UN COMPOSÉ IMMUNOMODULATEUR POUR LE TRAITEMENT D'UN LYMPHOME | [2024/06] | Entry into regional phase | 06.10.2023 | National basic fee paid | 06.10.2023 | Designation fee(s) paid | 06.10.2023 | Examination fee paid | Examination procedure | 06.10.2023 | Examination requested [2024/06] | 06.10.2023 | Date on which the examining division has become responsible | 07.05.2024 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 15.02.2024 | Renewal fee patent year 03 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [A]WO2020097403 (JUNO THERAPEUTICS INC [US]); | [A]WO2020210418 (CELGENE CORP [US]); | by applicant | US4452773 | US4690915 | US4795698 | US5200084 | US5219740 | EP0452342 | WO0014257 | US6040177 | US6060273 | US6207453 | US6410319 | US6451995 | US2002131960 | US2003170238 | US7070995 | US2007116690 | US7265209 | US7354762 | US7446190 | US7446179 | US7446191 | WO2009072003 | WO2010033140 | US2011003380 | WO2012129514 | US8324353 | US8339645 | EP2537416 | US8389282 | US8398282 | WO2013071154 | US2013149337 | US8479118 | WO2013123061 | WO2013126726 | US2013287748 | WO2013166321 | WO2014031687 | WO2014055668 | US8802374 | WO2014190273 | WO2015095895 | US2016152723 | WO2018023100 | US2019322647 | WO1991US08442 | WO1994US05601 |